Want to see AMLX full AI Analyst Report?
AMLX Stock Chart & Stats
$18.36
-$0.14(-3.78%)
At close: 4:00 PM EST
$18.36
-$0.14(-3.78%)
Day’s Range― - ―
52-Week Range$7.48 - $19.15
Previous CloseN/A
Volume98.90K
Average Volume (3M)1.66M
Market Cap
$1.89B
Enterprise Value$1.26K
Total Cash (Recent Filing)$279.77M
Total Debt (Recent Filing)$5.63M
Price to Earnings (P/E)―
Beta1.50
Next Earnings
Aug 06, 2026EPS Estimate
-0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.48
Shares Outstanding111,186,320
10 Day Avg. Volume1,173,600
30 Day Avg. Volume1,659,734
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)3.74
Price to Sales (P/S)0.00
P/FCF Ratio-9.25
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$26.29Price Target Upside43.17% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-1.41
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage Balance SheetThe company's balance sheet shows very low debt relative to equity, giving it financial flexibility to fund development and regulatory milestones without immediate refinancing. This durable low-leverage position reduces short-to-medium-term insolvency risk while clinical programs progress.
Pivotal Phase III Enrollment CompleteCompleting pivotal trial enrollment materially de-risks the timeline to a regulatory inflection point. A 90%‑powered study with NDA drafting in progress creates a clear, durable catalyst: positive readout enables submission and potential approval, shaping the firm's commercial outlook over the next 6–12 months.
Commercial Preparedness And Defined MarketActive build-out of commercial, market‑access and medical teams plus an expanded access program signals readiness to scale if approved. A quantifiable target population (~160k) and early field engagement support a credible go‑to‑market plan that underpins potential sustained revenue generation post-approval.
Bears Say
Revenue Collapse And Commercial Traction LossThe abrupt fall to zero reported revenue indicates a severe loss of product income and commercial traction. Without recurring product sales, the business fundamentally relies on clinical/regulatory outcomes and financing, increasing execution risk and making long‑term growth contingent on trial success and subsequent market uptake.
Sustained Negative Operating And Free Cash FlowPersistent large negative operating and free cash flow erodes cash reserves and forces continued reliance on capital markets or milestone receipts. Even with low debt, ongoing burn can compress runway, limit strategic optionality, and pressure R&D and commercial investment if clinical timelines delay or results are adverse.
Binary Dependence On LUCIDITY Amid Rising SpendThe company's near-term trajectory is highly concentrated on a single pivotal readout, while operating expenses are increasing and cash has declined year‑over‑year. This concentration creates a binary outcome where a negative trial result or additional delays could materially impair runway and necessitate dilutive financing or program cuts.
Amylyx Pharmaceuticals Inc News
AMLX FAQ
What was Amylyx Pharmaceuticals, Inc.’s price range in the past 12 months?
Amylyx Pharmaceuticals, Inc. lowest stock price was $7.48 and its highest was $19.15 in the past 12 months.
What is Amylyx Pharmaceuticals, Inc.’s market cap?
Amylyx Pharmaceuticals, Inc.’s market cap is $1.89B.
When is Amylyx Pharmaceuticals, Inc.’s upcoming earnings report date?
Amylyx Pharmaceuticals, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 18 days.
How were Amylyx Pharmaceuticals, Inc.’s earnings last quarter?
Amylyx Pharmaceuticals, Inc. released its earnings results on May 07, 2026. The company reported -$0.37 earnings per share for the quarter, missing the consensus estimate of -$0.338 by -$0.032.
Is Amylyx Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts Amylyx Pharmaceuticals, Inc.’s price is currently Undervalued.
Does Amylyx Pharmaceuticals, Inc. pay dividends?
Amylyx Pharmaceuticals, Inc. pays a Quarterly dividend of $0.42 which represents an annual dividend yield of N/A. See more information on Amylyx Pharmaceuticals, Inc. dividends here
What is Amylyx Pharmaceuticals, Inc.’s EPS estimate?
Amylyx Pharmaceuticals, Inc.’s EPS estimate is -0.35.
How many shares outstanding does Amylyx Pharmaceuticals, Inc. have?
Amylyx Pharmaceuticals, Inc. has 111,186,320 shares outstanding.
What happened to Amylyx Pharmaceuticals, Inc.’s price movement after its last earnings report?
Amylyx Pharmaceuticals, Inc. reported an EPS of -$0.37 in its last earnings report, missing expectations of -$0.338. Following the earnings report the stock price went down -5.355%.
Which hedge fund is a major shareholder of Amylyx Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in AMLX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Amylyx Pharmaceuticals Inc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$26.29 (43.17% Upside)
$26.29 (43.17% Upside)
Blogger Sentiment
Bullish
AMLX Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 307.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $51.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.7%
Last 30 Days ▼ 2.5%
Last 30 Days ▼ 2.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
101.89%
12-Months-Change
Fundamentals
Return on Equity
-55.68%
Trailing 12-Months
Asset Growth
33.65%
Trailing 12-Months
Company Description
Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
AMLX Stock 12 Month Forecast
Average Price Target
$26.29
▲(43.17% Upside)
Technical Analysis
BioCryst
―
Dianthus Therapeutics
―
Harmony Biosciences Holdings
―
Pharvaris
―
Biohaven Ltd.
―
Ownership Overview
8.03% Insiders
24.51% Mutual Funds
0.04% Other Institutional Investors
54.21% Public Companies and
Individual Investors